SURGERY PARTNERS DL -,01

Surgery Partners has filed binding contractual documents to sell its stakes in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health. The two facilities are valued at about $1.15 billion, with Surgery Partners receiving roughly $795 million. The company simultaneously confirmed its 2026 guidance (revenue $3.35–3.45 billion; adjusted EBITDA at least $530 million, each excluding the transaction) and emphasized that the proceeds will be used to focus on outpatient surgery centers. The announcement pushed the stock markedly higher intraday; Q2 results are expected on August 10. » Mais em de.investing.com

Surgery Partners agreed to sell Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for about $1.15 billion, after which the stock rose roughly 5.8%. The company expects to receive approximately $795 million in consideration for its ownership interests and a substantial cash inflow at closing, subject to customary purchase price adjustments. The deal still requires various approvals, including physician consents and expiration of Hart‑Scott‑Rodino waiting periods; the partnership with Intermountain Health will remain in place and the physician ownership stake at Mountain View Hospital will be unchanged. Surgery Partners calls the transaction the largest step in its portfolio-optimization strategy, affirms its prior 2026 guidance (revenue $3.35–3.45 billion, adjusted EBITDA at least $530 million) and says it will disclose further details on the financial impact after closing. » Mais em de.investing.com

Surgery Partners closed at $11.53, a 52-week low, after a 45.77% decline over the past six months and a 51.11% drop over 12 months. InvestingPro classifies the stock as volatile (beta 1.94) but considers it undervalued at the current level, citing price targets between $14 and $25. UBS affirmed a buy rating with a $21 target, while RBC cut its target to $20 but kept an outperform rating. Activist Ortelius Advisors is calling for a leadership change; investors are watching the company’s response amid weaker 2026 forecasts and unresolved M&A expectations. » Mais em de.investing.com